NanoViricides, Inc. President Dr. Anil R. Diwan Recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut...
March 31 2014 - 07:00AM
Business Wire
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) announced
today that Anil R. Diwan, Ph.D., President, Chairman, and
co-Founder of the Company was recognized as the “2014 Researcher of
the Year” by BusinessNewHaven, a business journal, and New Haven
Magazine, publications that serve the state of Connecticut.
The article was published in the February, 2014 issue of
BusinessNewHaven, and is reproduced on the Company’s website with
permission (www.nanoviricides.com/index.html#bnh-recognition).
BusinessNewHaven recognizes “Healthcare Heroes” in the state of
Connecticut every year. The heroes are chosen from all walks of
life in various categories. The magazine seeks to recognize
individuals particularly for their persistence, perseverance, novel
approaches, and potential for impact on society. The magazines
together have a combined circulation of over 40,000 in
Connecticut.
“We recognized Dr. Diwan as the Researcher of the Year because
we were impressed by his hard work, the ups and downs that he has
faced over his long career in making NanoViricides, Inc. happen,
and the fact that he did not quit in the face of adversity,” said
Mitchell Young, Publisher of Second Wind Media Ltd., of which
BusinessNewHaven Magazine is a part. “He was selected from several
other nominations, because he represents the essence that we seek
in a hero.”
“We at NanoViricides congratulate Anil for this recognition,”
said Dr. Eugene Seymour, MD, MPH, CEO of the Company. “We all know
the hard work and the brilliant technologies that he has brought
forth.”
“I am very pleased with this recognition,” said Dr. Diwan.
“There is still a long way ahead and I am committed to bringing our
revolutionary technologies to benefit patients.”
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Amanda Schuon,
310-550-7200info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Feb 2024 to Mar 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Mar 2023 to Mar 2024